Rosuvastatin effects on systemic oxidative stress, endogenous inflammation and main neoangiogenesis factors in patients with atherosclerosis

Aim. To investigate rosuvastatin effects on oxidative stress (OS), endogenous inflammation and neoangiogenesis process in patients with systemic atherosclerosis (SA).Material and methods. In total, 46 SA patients (mean age 56,5±2,2 years) were divided into two groups, comparable by clinical and functional parameters. Group I (n=24) received standard therapy, while Group II (n=22) was administered standard therapy plus rosuvastatin (10 mg/d). In all participants, serum lipid profile, in vitro Cu-ion oxidation of serum and high-density lipoproteins (HDL), concentrations of 3-nitrotyrosine (3-NT), high-sensitive C-reactive protein (hs-CRP), and interleukin-6 (IL-6), activity of secretory phospholipase A2 Type IIA (secPHLA2-IIA), and VEGF and PIGF factor levels were measured.Results. Moderate doses of rosuvastatin significantly decreased serum and HDL oxidation — by 34% (р